ArticleCancers2024

Preclinical Efficacy of VTX-0811: A Humanized First-in-Class PSGL-1 mAb Targeting TAMs to Suppress Tumor Growth.

Tatiana Novobrantseva et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.